Unicycive Therapeutics published a review on phosphate management challenges in kidney disease, highlighting patient perspectives and therapy limitations. Quiver AI Summary Unicycive Therapeutics ...

Nephrology > General Nephrology FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus Control — Advisors see need for alternatives, citing suboptimal efficacy and tolerance of approved ...

Reference Fong PS, Larive B, Kendrick C, et al. Effect of oral sodium bicarbonate on calcium-phosphate nephrolithiasis risk in chronic kidney disease: a secondary analysis of the BASE Pilot Tria l.

Use of oral sodium phosphate (OSP) for bowel cleansing prior to a colonoscopy is not associated with the risk of postprocedure acute kidney injury (AKI), according to a study published in Clinical ...

An additional trial showing a 'clinically relevant treatment effect' needed for approval in patients with kidney disease on dialysis, says the FDA in response to a new drug application.